

# **UNIHEALTH CONSULTANCY PRIVATE LIMITED**

**ANNUAL ACCOUNTS**

**FOR THE YEAR ENDED**

**31<sup>ST</sup> March 2023**

**AUDITORS:**  
**G. P. KAPADIA & CO.**  
**Chartered Accountants**  
**Mumbai-400001.**  
**Tel : 022-2265 4239/4313**  
**Email:info@gpkco.com**

# **UNIHEALTH CONSULTANCY PRIVATE LIMITED**

## **14TH ANNUAL REPORT 2022-2023**

### **BOARD OF DIRECTORS**

AKSHAY PARMAR  
ANURAG SHAH  
PARAG R SHAH

MANAGING DIRECTOR  
DIRECTOR  
WHOLE TIME DIRECTOR & CFO

### **REGISTERED OFFICE**

H-13/14, Everest, 9<sup>th</sup> floor  
156 Tardeo Road,  
Mumbai – 400 034  
Maharashtra

### **AUDITORS**

G. P. KAPADIA & CO.  
Chartered Accountants  
Mumbai. 400 001.

### **BANKERS**

Kotak Mahindra Bank Ltd.  
ICICI Bank Ltd  
Bank of Baroda

## INDEPENDENT AUDITORS' REPORT

**To the Members of  
Unihealth Consultancy Private Limited**

**Report on Audit of the Standalone Financial Statements**

### **Opinion**

We have audited the accompanying Standalone Financial Statements of **Unihealth Consultancy Private Limited** (the "Company"), which comprise the Standalone Balance Sheet as at March 31, 2023, the Standalone Statement of Profit and Loss, the Standalone Statement of Cash Flows for the year ended on that date, and notes to the Standalone Financial Statements including a summary of the significant accounting policies and other explanatory information (the "Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, its profit and its cash flows for the year ended on that date.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditors' Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone financial statements.

### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

**Information Other than the Standalone Financial Statements and Auditors' Report Thereon**

The Company's management and Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Company's Annual report, but does not include the Standalone financial statements and our auditor's report thereon.

Our opinion on the Standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Standalone Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

**Management's Responsibility for the Standalone Financial Statements**

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, Profit/loss and cash flows of the Company in accordance with the accounting principles generally accepted in India, including Accounting Standards (AS) specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls and ensuring their operating effectiveness and the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

**Auditors' Responsibility for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonable knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors:

- (i) In planning the scope of our audit work and in evaluating the results of our work; and
- (ii) To evaluate the effect of any identified misstatements in the Standalone Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 (the "Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. A. As required by Section 143(3) of the Act, based on our audit, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Standalone Balance Sheet, the Standalone Statement of Profit and Loss, the Standalone Statement of Cash Flows dealt with by this Report are in agreement with the relevant books of account.
  - d) In our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rule, 2014.
  - e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164(2) of the Act.

**G. P. KAPADIA & CO.**

- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, the said report is not applicable to the Company vide notification G.S.R. 583[E] dated June 13, 2017.
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a) The company has disclosed the effect of pending litigations which would impact its financial positions. (Note 26 of the Standalone Financial Statements)
  - b) The company did not have any material foreseeable losses on long term contracts including derivative contracts.
  - c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - d)
    - (i) The Management has represented us that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either borrowed funds or share premium or any other sources or kind of funds) to any other person or entities, including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or Provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
    - (ii) The Management has represented us that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received from any person or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
    - (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representation under sub clause (i) and (ii) of Rule 11(e) of the companies (Audit and Auditors) Rules 2014, as provided under (d) (i) and (ii) above, contains any material misstatement.

**G. P. KAPADIA & CO.**

- (e) The company has not declared or paid any dividend during the year. Hence, compliance with section 123 of the Companies Act, 2013 is not applicable.
- (f) As proviso to rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable for the Company only with effect from 1st April 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is not applicable.
- C. With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.

**For G.P. Kapadia & Co.**

**Chartered Accountants**

**(Firm's Registration No.104768W)**

Digitally signed by ATUL

BABUBHAI DESAI

Date: 2023.08.21 19:02:26

+05'30'

**Atul Desai**

**Partner**

**Membership No. 030850**

**Date: 21<sup>st</sup> August 2023**

**Place: Mumbai**

**UDIN: 23030850BGRKGG4091**



**“ANNEXURE A” TO THE INDEPENDENT AUDITORS’ REPORT**

[Referred to in paragraph 1 under ‘Report on Other Legal and Regulatory Requirements’ in the Independent Auditor’s Report of even date to the members of **Unihealth Consultancy Private Limited** on the Standalone Financial Statements for the year ended March 31, 2023]

- i. In respect of the Company’s Property, Plant and Equipment and Intangible asset:
  - a. (A) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.  
(B) Further, the company has also maintained proper records showing full particulars of intangible assets.
  - b. As per information provided and explanation given to us, the Property, Plant & Equipment have been physically verified by the management on reasonable interval. In our opinion, the frequency of verification of the fixed assets by the management is reasonable having regards to the size of the Company and the nature of its assets. According to the information and explanation given to us, no material discrepancies were noticed on such verification.
  - c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of the immovable properties disclosed in the Standalone financial statements are held in the name of the Company.
  - d. As per information provided and explained to us by the company, the Company has not revalued its Property, Plant and Equipment and intangible assets during the year.
  - e. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
  
- ii. (a) The company does not have any inventory and hence reporting under clause 3(ii)(a) of the Order is not applicable.  
  
(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned any working capital limit in excess of five crore rupees, in aggregate, from banks and

financial institutions on the basis of security of the current assets at any point of the time of the year. Accordingly, clause 3(ii)(b) of the order is not applicable to the Company.

iii. According to the information and explanations given to us and on the basis of our examination of the books and records by us, the Company has made investments in and provided unsecured loans, to companies and other parties during the year;

(a) During the year the company has provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity:

A. the aggregate amount during the year, and balance outstanding at the balance sheet date with respect to such loans to subsidiaries and joint ventures is as follows:

	Guarantees	Security	Loans (in Lakhs)	Advances in the nature of Loans
<b>Aggregate amount granted/ provided during the year</b>				
<b><u>Subsidiaries</u></b>				
- Biohealth Limited	-	-	36.02	-
- Unihealth Tanzania Limited	-	-	41.11	-
<b><u>Joint Venture</u></b>				
- Victoria Hospital Limited	-	-	656.44	-
<b>Total</b>	-	-	<b>733.57</b>	-
<b>Balance outstanding as at balance sheet date in respect of above cases</b>				
<b><u>Subsidiaries</u></b>				
- Biohealth Limited	-	-	73.06	-
- Unihealth Tanzania Limited	-	-	41.11	-
<b><u>Joint Venture</u></b>				
- Victoria Hospital Limited	-	-	1,370.44	-
<b>Total</b>	-	-	<b>1484.61</b>	-

**G. P. KAPADIA & CO.**

B. the aggregate amount during the year, and balance outstanding at the balance sheet date with respect to such loans to parties other than subsidiaries, joint ventures is as follows:

	<b>Guarantees</b>	<b>Security</b>	<b>Loans</b>	<b>Advances in the nature of Loans</b>
<b>Aggregate amount granted/ provided during the year</b>				
<b><u>Employees</u></b>				
- Raunak Dhanuka	-	-	1.00	-
<b>Total</b>	-	-	<b>1.00</b>	-
<b>Balance outstanding as at balance sheet date in respect of above cases</b>				
<b><u>Employees</u></b>				
- Jatin Dimble	-	-	1.39	-
- Jaywant M H	-	-	0.07	-
- Raunak Dhanuka	-	-	27.00	-
<b>Total</b>	-	-	<b>28.46</b>	-

- (b) In our opinion and according to the information and explanations given to us, the investments made and the terms and conditions of the grant of all loans provided are not prejudicial to the company's interest;
- (c) In respect of loans, the schedule of repayment of principal and payment of interest has been stipulated. No repayment of principal or interest was due in the current year.
- (d) In respect of loans granted by the Company, there is no amount overdue for more than 90 days as at the Balance Sheet date.
- (e) None of the loans or advances in the nature of loans has fallen due during the year, or has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties.
- (f) There are no loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment, granted during the year.

**G. P. KAPADIA & CO.**

- iv. In our opinion and according to the information and explanations given to us, in respect of loans, investments, guarantees, and security the Company has complied with section 185 and 186 of the Companies Act, 2013.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any Deposit from the public within the meaning of Section 73 to 76 or any other relevant provision of the Act and the Rules framed there under. Accordingly, paragraph 3(v) of the order is not applicable to the company.
- vi. The Central Government has not prescribed the maintenance of cost records under section 148(1) of the Act for services rendered by the Company; accordingly paragraph 3(vi) of the order is not applicable to the Company.
- vii. (a) According to the information and explanation given to us, the company is generally regular in depositing undisputed statutory dues including Goods and Service tax, Provident fund, Employees' state Insurance, Income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities during the year and no such dues are outstanding as at March 31, 2023 for a period of more than six months from the date they became payable.

(b) According to the information and explanation given to us, there are no dues of Goods and Service tax, Provident fund, Employees' state Insurance, Income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues, which have not been deposited on account of any dispute other than those mentioned below:

Name of the Statute	Nature of the dues	Amount Unpaid (in Lakhs)	Period to which amount relates	Forum where dispute is pending
Income Tax Act, 1961	Mis-match in TDS	0.22	AY-2013-14	Income Tax Officer
Income Tax Act, 1961	DDT re-grossed up by ITO	0.09	AY-2016-17	Income Tax Officer
Income Tax Act, 1961	As per Assessment Order	411.35	AY-2017-18	National Faceless Appeal Centre ( Appeals ), Delhi
Income Tax Act, 1961	As per Assessment Order	394.41	AY-2018-19	National Faceless Appeal Centre ( Appeals ), Delhi

- viii. In our opinion and according to the information and explanations given to us, the company does not have any transactions not recorded in the books of account which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax, 1961 (43 of 1961).

**G. P. KAPADIA & CO.**

- ix. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company is having borrowings from Banks, Financial Institutions and other lenders. However, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or other lender.
- (c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the Standalone Financial Statements of the company, we report that the Company has borrowed short term funds in the form of Bank Overdraft during the year. The same have been used for the purpose for which the loans were obtained.
- (e) According to the information and explanations given to us and on an overall examination of the Standalone financial statements of the company, we report that the company has taken funds from following entities/ persons during the year, and advanced to subsidiaries and joint ventures out of it, but not specifically on account of or to meet the obligations of its subsidiaries and joint ventures as per details below:

<b>Nature of fund taken</b>	<b>Name of lender</b>	<b>Amount involved (in Lakhs)</b>	<b>Name of the subsidiary, joint venture, associate</b>	<b>Relation</b>	<b>Nature of Transaction for which funds utilized</b>
Loan from Promoter and Shareholders	Akshay M Parmar, Mayuri A Parmar, Prafulla M Parmar, Shantilal B Kataria	344.25	Victoria Hospital Limited Biohealth Limited Unihealth Tanzania Limited.	Joint Venture Subsidiary Subsidiary	Loans/advance to Subsidiary, JV
Loan from Others	Mahendra H Parmar (Father of Promoter)	250.40	Victoria Hospital Limited Biohealth Limited Unihealth Tanzania Limited.	Joint Venture Subsidiary Subsidiary	Loans/advance to Subsidiary, JV

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

x. (a) In our opinion and according to the information and explanation given to us, the company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) during the year. Thus, reporting under clause 3(x)(a) of the Order is not applicable to the Company.

(b) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, clause 3(x)(b) of the Order are not applicable to the Company.

xi. (a) According to information and explanation provided to us, no fraud by the company or any fraud on the company has been noticed or reported during the year.

(b) In our opinion and according to the information and explanation given to us, no report has been filed as prescribed ADT – 4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) In our opinion and according to the information and explanation given to us, during the year there were no complaint's received/noted from any whistle blowers.

xii. The Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the Order is not applicable to the Company.

xiii. According to the information and explanations given to us and based on examination of records, transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Standalone Financial Statements as required by the applicable accounting standards. Section 177 of the Act is not applicable to the Company.

xiv. In our opinion and according to the information and explanation given to us and based on our examination, the company is not required to have an internal audit system as per provisions of the Companies Act 2013. Accordingly, paragraph 3(xiv) (a) to (b) of the Order is not applicable to the company.

xv. According to the information and explanations given to us and based on examination of records, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable to the Company.

**G. P. KAPADIA & CO.**

- xvi. In our opinion, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of paragraph 3(xvi) of the Order are not applicable to the Company and hence not commented upon.
- xvii. In our opinion and according to the information and explanation given to us, The Company has not incurred any cash losses in the financial year and in the immediately preceding financial year. Accordingly, paragraph 3(xvii) of the Order is not applicable to the company.
- xviii. There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the Standalone Financial Statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- xx. In our opinion and according to the information and explanation given to us the provisions of section 135 of the Companies Act, 2013 are not applicable to the Company. Accordingly, clauses 3(xx)(a) and (b) of the Order are not applicable to the Company.
- xxi. According to the information and explanations given to us and on the basis of our examination, no qualifications or adverse remarks is reported by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports to the extent applicable for the Indian Subsidiary Company, included in the consolidated financial statements.

**For G.P. Kapadia & Co.**  
**Chartered Accountants**  
**(Firm's Registration No.104768W)**

Digitally signed by ATUL  
BABUBHAI DESAI  
Date: 2023.08.21 19:03:04 +05'30'

**Atul Desai**  
**Partner**  
**Membership No. 030850**  
**Date: 21<sup>st</sup> August 2023**  
**Place: Mumbai**  
**UDIN: 23030850BGRKGG4091**

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**

**CIN : U85100MH2010PTC200491**

**Standalone Balance Sheet as at March 31, 2023**

Particulars	Note No.	As at 31st March, 2023 (₹ in Lakhs)	As at 31st March, 2022 (₹ in Lakhs)
<b>I. EQUITY AND LIABILITIES</b>			
<b>(1) Shareholder's Funds</b>			
(a) Share Capital	3	138.95	134.19
(b) Reserve & Surplus	4	1,127.91	517.13
(c) Money received against share warrants		-	-
		<b>1,266.86</b>	<b>651.32</b>
<b>(2) Share Application Money Pending Allotment</b>			
<b>(3) Non-Current Liabilities</b>			
(a) Long-term borrowings	5	1,110.05	1,130.26
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities		-	-
(d) Long term provisions		-	-
		<b>1,110.05</b>	<b>1,130.26</b>
<b>(4) Current Liabilities</b>			
(a) Short-term borrowings	6	97.72	30.04
(b) Trade payables			
(i) Total outstanding dues of micro enterprises and small enterprises	7	0.55	0.55
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises		2.50	3.77
(c) Other current liabilities	8	38.82	36.22
(d) Short-term provisions	9	18.56	-
		<b>158.15</b>	<b>70.58</b>
<b>Total</b>		<b>2,535.06</b>	<b>1,852.16</b>
<b>II. ASSETS</b>			
<b>(1) Non-current assets</b>			
<b>(a) Property, Plant and Equipment and Intangible Asset</b>			
(i) Property, Plant and Equipment	10	141.86	150.10
(ii) Intangible assets		0.31	0.31
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments	11	633.87	614.62
(c) Deferred tax assets (net)	12	22.32	-
(d) Long term loans and advances	13	1,484.61	688.11
(e) Other non-current assets	14	91.15	64.85
		<b>2,374.12</b>	<b>1,517.99</b>
<b>(2) Current assets</b>			
(a) Current Investments		-	-
(b) Inventories		-	-
(c) Trade receivables	15	62.44	209.84
(d) Cash and cash equivalents	16	3.65	14.92
(e) Short-term loans and advances	17	34.67	34.64
(f) Other current assets	18	60.18	74.77
		<b>160.94</b>	<b>334.17</b>
<b>Total</b>		<b>2,535.06</b>	<b>1,852.16</b>
Significant accounting policies	2		
The accompanying notes are an integral part of the financial statements	2-44		

As per our report of even date attached

For G. P. Kapadia & Co  
Chartered Accountants  
Firm's Registration No: 104768W

*Atul B Desai*  
Atul B Desai  
Partner  
Membership No. : 30850  
Place : Mumbai  
Date: August 21st, 2023




For and on behalf of Board of  
Unihealth Consultancy Private Limited

*Akshay M Parmar*  
Akshay M Parmar  
Managing Director  
DIN:01533004

*Prajakta S Bhor*  
Prajakta S Bhor  
Company Secretary  
Membership No.: A55171

*Anurag R Shah*  
Anurag R Shah  
Director  
DIN:02544806

*Parag R Shah*  
Parag R Shah  
Whole Time Director  
& Chief Financial Officer  
DIN: 07773456





**UNIHEALTH CONSULTANCY PRIVATE LIMITED**

**CIN : U85100MH2010PTC200491**

**Standalone Statement of Profit and Loss for the year ended March 31, 2023**

	Particulars	Note No.	Year ended March 31, 2023 (₹ in Lakhs)	Year ended March 31, 2022 (₹ in Lakhs)
I.	Revenue from operations	19	192.49	161.48
II.	Other income	20	178.62	94.48
III.	<b>Total Income (I + II)</b>		<b>371.11</b>	<b>255.96</b>
IV.	<u>Expenses:</u>			
	Cost of Materials consumed		-	-
	Purchase of Stock-in-Trade		-	-
	Changes in inventories of finished goods, work-in-progress and stock-in-trade		-	-
	Employee benefit expenses	21	52.52	44.13
	Finance cost	22	115.41	118.75
	Depreciation and amortization expense	10	8.30	9.30
	Other expenses	23	83.51	36.00
	<b>Total Expenses</b>		<b>259.74</b>	<b>208.18</b>
V.	<b>Profit before Exceptional and Extraordinary items and Tax</b>		<b>111.37</b>	<b>47.78</b>
VI.	Exceptional items		-	-
VII.	<b>Profit before Extraordinary items and Tax (V-VI)</b>		<b>111.37</b>	<b>47.78</b>
VIII.	Extraordinary Items		-	-
IX.	<b>Profit before Tax (VII-VIII)</b>		<b>111.37</b>	<b>47.78</b>
X.	<u>Tax expense:</u>			
	(1) Current Tax		-	-
	(2) Deferred Tax (credit)		(22.32)	-
XI.	Profit (Loss) for the period from continuing operations (VII-VIII)		-	-
XII.	Profit (Loss) from discontinuing operations		-	-
XIII.	Tax expense of discontinuing operations		-	-
XIV.	Profit (Loss) from discontinuing operations (after tax) (XII-XIII)		-	-
XV.	<b>Profit/(Loss) for the period (XI+XIV)</b>		<b>133.69</b>	<b>47.78</b>
XVI.	Earning per equity share			
	(Nominal value of share of ₹ 10 (Previous year ₹ 10))			
	(1) Basic (in ₹)	24	9.96	3.56
	(2) Diluted (in ₹)		9.96	3.56
	Significant accounting policies	2		
	The accompanying notes are an integral part of the financial statements	2-44		

As per our report of even date attached

**For G. P. Kapadia & Co**  
Chartered Accountants  
Firm's Registration No: 104768W

**Atul B Desai**  
Partner  
Membership No. : 30850  
Place : Mumbai  
Date: August 21st, 2023



**For and on behalf of Board of**  
**Unihealth Consultancy Private Limited**

**Akshay M Parmar**  
Managing Director  
DIN:01533004

**Prajakta Suresh Bhor**  
Company Secretary  
Membership No.: A55171

**Anurag R Shah**  
Director  
DIN:02544806

**Parag Shah**  
Whole Time Director  
& Chief Financial Officer  
DIN: 07773456



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
CIN : U85100MH2010PTC200491  
Standalone Cash Flow Statement for the year ended March 31, 2023

Particulars	As at 31st March, 2023 (₹ in Lakhs)	As at 31st March, 2022 (₹ in Lakhs)
<b>A Cash flow from operating activities</b>		
Net profit before tax	111.37	47.78
<b>Adjustments for:</b>		
Depreciation/amortization	8.30	9.30
Profit on sale of Fixed Asset	-	-
Finance Cost	115.41	118.75
Foreign exchange (gain)/Loss	(76.54)	(21.58)
Miscellaneous Income	(0.02)	-
Rent Received	(3.50)	(2.94)
Interest on refunds from income tax	(18.15)	0.07
Interest on FD	(0.36)	(0.48)
Interest on Loan given	(98.19)	(69.48)
<b>Operating profit before working capital changes</b>	<b>38.32</b>	<b>81.42</b>
<b>Changes in assets and liabilities:</b>		
(Increase) / decrease in Trade Receivables	147.40	(61.41)
(Increase) / decrease in Short term Loans and Advances	(0.04)	695.73
Increase / (decrease) in Current Liabilities	2.59	(16.05)
Increase / (decrease) in Short term Provisions	18.56	-
Increase / (decrease) in Non Current Liabilities	-	(331.21)
Increase / (decrease) in Trade Payables	(1.27)	(3.60)
(Increase) / decrease in Other Non Current Assets	(26.30)	(64.85)
(Increase) / decrease in Other Current Assets	14.59	(74.77)
<b>Cash (used in) generated from operating activities</b>	<b>193.85</b>	<b>225.26</b>
Income tax paid	-	-
<b>Net cash from/ (used in) from operating activities (A)</b>	<b>193.85</b>	<b>225.26</b>
<b>B Cash flow from Investing activities</b>		
(Increase) / decrease in Long term Loans & Advances	(796.49)	(686.18)
Interest on Loan Given	98.19	69.48
Interest on Fixed Deposit	0.36	0.48
Sale of Fixed Asset	-	-
Purchase of Holding in subsidiary	(19.25)	-
Rent Received	3.50	2.94
Purchase of fixed assets	(0.06)	-
<b>Net cash from/ (used in) from investing activities (B)</b>	<b>(713.75)</b>	<b>(613.28)</b>
<b>C Cash flow from Financing activities</b>		
Proceeds/ (Repayment) of Borrowings	547.48	489.80
Foreign exchange (gain)/Loss	76.54	21.58
Miscellaneous Income	0.02	-
Finance cost	(115.41)	(118.75)
<b>Net cash from / (used in) from financing activities (C)</b>	<b>508.63</b>	<b>392.63</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>(11.27)</b>	<b>4.61</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>14.92</b>	<b>10.31</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>3.65</b>	<b>14.92</b>
Significant accounting policies	2	
The accompanying notes are an integral part of the financial	2-44	

As per our report of even date attached

**Notes:**

- The cash flow statement has been prepared in accordance with the requirements of Accounting standard - 3 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.
- The figures in brackets indicate outflows of cash and cash equivalents.
- Previous year's figures have been regrouped, rearranged wherever necessary.
- Pursuant to a resolution passed by Board of Directors of the company, at their meeting held on March 30, 2023, Conversion of Loan of ₹500 Lacs into 47,619 no. of Equity shares of the company issued at a price of ₹ 1050 (including premium of ₹ 1040) in case of shareholder Mr. ShantiLal Kataria was approved.

For G. P. Kapadia & Co  
Chartered Accountants  
Firm's Registration No: 104768W

*Atul B Desai*

Atul B Desai  
Partner  
Membership No. : 30850  
Place : Mumbai  
Date: August 21st, 2023




For and on behalf of Board of  
Unihealth Consultancy Private Limited

*Akshay M Parmar*  
Akshay M Parmar  
Managing Director  
DIN:01533004

*Prajakta*  
Prajakta Suresh Bhor  
Company Secretary  
Membership No.: A55171

*Anurag R Shah*  
Anurag R Shah  
Director  
DIN:02544806

*P. Shah*  
Parag Shah  
Whole Time Director  
& Chief Financial Officer  
DIN: 07773456



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

**Note 44**  
**Accounting Ratios**

Sr.No.	Ratios	Numerator	Denominator	31-03-2023	31-03-2022	% of Change	Reason for Change
1	Current Ratio (in times)	Current Assets	Current Liabilities	1.02	4.73	-79%	Increase in Current Liabilities
2	Debt Equity Ratio (in times)	Long Term Debt + Short term debt	Shareholder's Equity	0.95	1.78	-46%	Increase in Shareholder's Equity by a higher percentage than Debt
3	Debt Service coverage ratio (in times)	Earnings available for Debt Services = Net Profit before taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like	Debt Services = Interest & Lease Payments + Principal Repayments	0.18	0.14	29%	Increase in Profit
4	Return on Equity Ratio (in %)	Profit after Tax	Average Networth	13.94%	7.62%	83%	Higher percentage of increase in Profit
5	Inventory Turnover Ratio (in times)	COGS	Average Inventory	NA	NA	NA	NA
6	Trade Receivables turnover ratio (in times)	Net Credit Sales	Average trade receivables	1.41	0.90	57%	Increase in sales and reduction in Trade receivables
7	Trade payables turnover ratio (in times)	Total Credit Purchases	Average Trade Payables	NA	NA	NA	NA
8	Net Capital Turnover Ratio (in times)	Sales	Working capital (CA-CL)	68.85	0.61	11138%	Increase in sales
9	Net profit ratio (in %)	Net Profit	Sales	69.45%	29.59%	135%	net Profit is higher than increase in sales
10	Return on Capital employed (in %)	Profit before tax and interest expenses	Capital employed = Total Assets - Current	9.54%	9.35%	2%	NA
11	Return on investment (in %)	Net Profit	Investment*	NA	NA	NA	NA


\*Company is having Nil (P. Y. - Nil) Investments.


For G. P. Kapadia & Co  
Chartered Accountants  
Firm's Registration No: 104768W


  
Atul B Desai  
Partner  
Membership No. : 30850  
Place : Mumbai  
Date: August 21st, 2023




For and on behalf of Board of  
Unihealth Consultancy Private Limited

  
Akshay M Parmar  
Managing Director  
DIN:01533004

  
Anurag R Shah  
Director  
DIN:02544806

  
Prajakta Suresh Bhor  
Company Secretary  
Membership No.: A5517

  
Parag Shah  
Whole Time Director  
& Chief Financial Officer  
DIN: 07773456



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

**1. Corporate Information**

Unihealth Consultancy Private Limited was incorporated on 26/02/2010 having CIN U85100MH2010PTC200491 issued by the Registrar of companies, Maharashtra, Mumbai. The Company is predominantly engaged in business of Medical Tour Operator and Health Consultancy Service & Trader in Medical Equipments.

The Company is in process of getting listed on Small and Medium Enterprise ("SME") platform of National Stock Exchange (NSE).

**2. Significant Accounting Policies**

**2.01 Basis of preparation of financial statements:**

The financial statements have been prepared on a going concern basis under the historical cost convention, the applicable Accounting Standards as notified under the Companies (Accounting Standards) Rules, 2006 ("AS") and the relevant provisions of the Companies Act, 1956 ("the Act") (which continue to be applicable in respect of section 133 of the Companies Act, 2013 in term of General Circular 15/2013 dated 13th September, 2013 of the Ministry of Corporate Affairs), as adopted consistently by the Company.

The Company follows mercantile system of accounting and recognizes significant items of income and expenditure on accrual basis.

**2.02 Classification of Assets and Liabilities as Current and Non-Current:**

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III of the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

**2.03 Use of estimates:**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reported period. The estimates and assumptions used in the accompanying financial statements are based upon management's evaluation of the relevant facts and circumstances as of the date of financial statements. Actual results may differ from the estimates used in preparing the accompanying financial statements. Any revision to accounting estimates is recognized prospectively in current and future periods.

**2.04 Property, plant and equipment :**

Tangible Fixed Assets :

Tangible fixed assets are carried at the cost of acquisition or construction, less accumulated depreciation/accumulated impairment. The cost of fixed assets comprises of its purchase price, including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use.

Intangible Fixed Assets :

Intangible fixed assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization.

Gains/losses arising from retirement or disposal of fixed assets which are carried at cost are recognised in the Statement of Profit and Loss.



*Omama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**

**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

Capital Work in Progress:

The Company is not having any Capital Work in Progress, hence accordingly no ageing schedule has been disclosed separately.

**2.05 Depreciation & Amortization:**

Depreciation on tangible fixed assets is provided using the Written Down Value Method based on the useful lives of the assets as estimated by the management and is charged to the Statement of Profit and Loss as per the requirement of Schedule II of the Companies Act, 2013.

Intangible Assets are to be amortized on a Straight Line basis over the estimated useful economic life.

The Company has used following useful lives of the Property, Plant & Equipment to provide Depreciation.

No.	Nature of Assets	Estimated Useful life of the Assets
1	Building	60 Years
2	Furnitures & Fixtures	10 Years
3	Electrical Equipment	3 Years
4	Computer	3 Years
5	Office Equipment	5 Years
6	Vehicle	10 Years
7	Software License	5 Years

Amortisation is recognised on a written down value over their estimate useful life.

Intangible Assets and their useful lives are as under:

No.	Nature of Assets	Estimated Useful life of the Assets (in Years)
1	Software License	5 Years

**2.06 Impairment of Assets :**

Consideration is given at each balance sheet date to determine whether there is any indication of impairment of the carrying amount of the Company's fixed assets. If any indication exists, an asset's recoverable amount is estimated. An impairment loss is recognized whenever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value based on an appropriate discount factor.

Reversal of impairment losses recognized in prior years is recorded when there is an indication that the impairment losses recognized for the asset no longer exists or has decreased. However, the increase in carrying amount of an asset due to reversal of an impairment loss is recognized to the extent it does not exceed the carrying amount that would have been determined (net of depreciation) had no impairment loss been recognized for the asset in prior years.

**2.07 Borrowing Cost :**

Borrowing costs that are attributable to acquisition or construction of qualifying assets are capitalized as a part of cost of such assets upto the commencement of commercial operations. A qualifying assets is the one that necessarily takes substantial period of time to get ready for intended use. Other borrowing costs are recorded as an expense in the year in which they are incurred.

The amount of exchange difference not exceeding the difference between interest on local currency borrowings and interest on foreign currency borrowings is considered as borrowing costs.



*Amal*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

**2.08 Investment:**

All long term investments are to be stated at cost. Provision for diminution, if any, in the value of investments is to be made to recognize a decline, other than temporary, in the opinion of the management.

Current investments are to be carried at the lower of cost and fair value, determined on a category-wise basis.

**2.09 Inventories:**

**Finished goods:**

Finished goods are valued at lower of cost and net realizable value.

**2.10 Revenue Recognition:**

Revenue is recognized to the extent it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

**Revenue from sale of product:**

Sale of goods is recognized as revenue when the significant risks and rewards of ownership of the goods have passed to the buyer.

**Revenue from rendering of Service :**

Revenue from rendering of service is recognised as the service is performed, either by the proportionate completion method or the by the completed service contract method.

**Other Income:**

The company has entered into lease agreement with its subsidiaries for space allocation to develop their business area by charging amount by way of Rent. The difference amount not realized in course of payments received from abroad customers are taken as foreign exchange gain/loss on particular date. The long dues which are likely to be not recoverable in future have been decided by management for providing for write back/write off wherever necessary. Interest income is accounted on accrual basis.

**2.11 Foreign Currency Transactions:**


**Initial recognition:**

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction. Non Monetary Items are recorded at the exchange rate prevailing as on the date of transaction.

**Subsequent recognition:**

Monetary assets and liabilities such as foreign currency receivables, payables, borrowings outstanding at the year-end are translated at the year-end rate. Resultant exchange difference arising on realisation / payment or translation at year end is recognized as income or expense in the year in which they arise.

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**

**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

**2.12 Taxation:**

Income tax expense comprises current tax expense and deferred tax.

Current Taxes :- Provision for current income-tax is recognized in accordance with the provisions of the Income-tax Act, 1961 and is made annually based on the tax liability after taking credit for tax allowance and exemptions.

Deferred Taxes :- The deferred tax charge or credit and the corresponding deferred tax liabilities or assets is recognized for the future tax consequence attributable to the timing differences between the profits/ losses offered for income taxes and profits/ losses as per the financial statements. Deferred tax assets and liabilities are measured using the tax rates and the tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in future; however, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed as at each balance sheet date and written down or written up to reflect the amount that is reasonable/virtually certain (as the case may be) to be realized.

**2.13 Provisions and Contingencies :**

The Company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources would be required to settle the obligation, the provision is reversed. Provision is not discounted to its present value.

A disclosure for a contingent liability is made when there is a possible obligation arising from the past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more future events not wholly within the control of the Company or a present obligation that arises from the past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

Contingent assets are not recognized in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

**2.14 Cash and cash equivalents :**

Cash & cash equivalents for the purpose of cash flow statement comprises cash at bank and in hand, demand deposits with banks, other short term highly liquid investments with original maturities of three months or less.

**2.15 Earnings per share :**

Basic earnings per share are computed by dividing the net profit after tax by the weighted average number of equity shares outstanding during the period.

**2.16 Related party transactions :**

Transactions with related parties in the ordinary course of the Company's business are detailed in Note No. 25 to the financial statements.



*Rmama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

**2.17 Events Occurring after Balance Sheet Date :**

Events that occur between balance sheet date and date on which these are approved, might suggest the requirement for an adjustment(s) to the assets and the liabilities as at balance sheet date or might need disclosure.

(a) Adjusting Events: Adjustments are required to be made in the Financial Statements for events which occur after balance sheet date which offer added information substantially affecting the determination of the amounts which relates to the conditions that existed at balance sheet date.

(b) Non-Adjusting Events: Adjustments aren't required to the Financial Statements for events which occur after balance sheet date, in case such events don't relate to the conditions which existed at balance sheet date.

There're events which, though occurring after balance sheet date, are sometimes presented in financial statements because of their special nature or due to statutory requirements.

**2.18 Employee Benefit :**

**Short term Employee Benefits**

Employee benefit payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries, wages and bonus. The undiscounted amount of short-term employee benefits to be paid in exchange for employee services is recognised as an expense as the related service is rendered by employees.

**Provident Fund**

As per the Employees Provident Funds and Miscellaneous Provision Act, 1952 employees of the Company are entitled to receive benefits under the provident fund & family pension fund which is a defined contribution plan. These contributions are made to the fund administered and managed by Government of India. The Company's contribution to the schemes is recognized as expense in the profit and loss account during the period in which the employee renders the related services. The Company has no other obligation to the plans beyond its monthly compensations.

**Defined benefits plan**

The company's gratuity benefit scheme is a unfunded defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, that benefit is discounted to determine its present value.

The calculation of company's obligation is performed annually by qualified actuary using the projected unit credit method.

The company recognises all actuarial gains and losses in the Statement of Profit and Loss.

The company recognises all the actuarial gains and losses immediately in the Statement of Profit and Loss. All expenses related to defined benefit plans are recognized in employee benefits expense in the Statement of Profit and Loss.

**2.17 AS-17 Segment Reporting:**

AS-17 'Segment Reporting' is not applicable to company since the company has only single line of business



*Uma ma*



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

(₹ in Lakhs)

**Note 3**  
**Share Capital**

Particulars	As on March 31, 2023		As on March 31, 2022	
	No. of Shares	Amount	No. of Shares	Amount
<b>Authorised capital</b>				
Equity Shares of ₹ 10 each (Note 3.1)	1,70,00,000	1,700.00	15,00,000	150.00
Preference Shares of ₹ 100 each	-	-	2,50,000	250.00
	<b>1,70,00,000</b>	<b>1,700.00</b>	<b>17,50,000</b>	<b>400.00</b>
<b>Issued, subscribed and fully paid up share capital</b>				
Equity Shares of ₹ 10 each (Note 3.2)	13,89,494	138.95	13,41,875	134.19
<b>Total</b>	<b>13,89,494</b>	<b>138.95</b>	<b>13,41,875</b>	<b>134.19</b>

**Note 3.1.** During the year, the authorised share capital of the Company ₹400 Lakhs consisting of 15,00,000 Equity Shares of ₹10 each and 2,50,000 9% Cumulative Redeemable Preference Shares of ₹100 each are reclassified to ₹400 Lakhs divided into 40,00,000 Equity Share of ₹10 each. Further, the Company has increased the authorised share capital of the Company from ₹ 400 Lakhs consisting of 40,00,000 Equity Shares of ₹ 10 each to ₹ 1700 Lakhs consisting of 1,70,00,000 Equity Shares of ₹ 10 each.

**3.2.** During the year, loan of Shaantika Kataria of ₹ 500 Lakhs has been converted into 47619 Equity Shares of face value of ₹ 10 each at a premium of ₹ 1040.

**a) Reconciliation of the shares outstanding at the beginning and end of the reporting period**

Particulars	March 31, 2023		March 31, 2022	
	No. of shares	Amount	No. of shares	Amount
Equity shares of ₹ 10 each fully paid up				
At the beginning of the year	13,41,875	134.19	13,41,875	134.19
Issued during the year	47,619	4.76	-	-
Bought back during the year	-	-	-	-
<b>Outstanding at the end of year</b>	<b>13,89,494</b>	<b>138.95</b>	<b>13,41,875</b>	<b>134.19</b>

**b) Details of shareholders holding more than 5% Equity shares in the Company**

Particulars	March 31, 2023		March 31, 2022	
	% holding in	No. of shares	% holding in	No. of shares
<b>Equity shares of Rs. 10 each fully paid</b>				
Anurag Ratan Kumar Shah	44.98%	6,25,000	46.58%	6,25,000
Akshay Mahendra Parmar	37.60%	5,22,500	23.29%	3,12,500
Prafulla Mahendra Parmar	7.38%	1,02,495	23.29%	3,12,495
	<b>89.96%</b>	<b>12,49,995</b>	<b>93.15%</b>	<b>12,49,995</b>

**c) Terms / rights attached to equity shares**

- The Company has only one class of equity shares having a par value of ₹10 per equity share held.
- Each share holder is eligible for one vote per share.
- If any dividend is proposed by the Board of Directors than the same is subject to approval of the Shareholders in the ensuing annual general meeting except in case of interim dividend.
- In the unlikely event of liquidation of the company the equity shareholders are eligible to receive the residual value of assets of the company if any after all secured and unsecured creditors of the company are paid off, in the proportion of their shareholding in the company.

**Details of shares held by the Promoters in the Company FY 2022-2023**

Sr. No	Name of the Promoter	No of Shares	% of Total Shares	% of change during the year
1	Anurag Ratan Kumar Shah	6,25,000	44.98%	-3.42%
2	Akshay Mahendra Parmar	5,22,500	37.60%	61.47%
	<b>Total</b>	<b>11,47,500</b>	<b>82.58%</b>	

**Details of shares held by the Promoters in the Company FY 2021-2022**

Sr. No	Name of the Promoter	No of Shares	% of Total Shares	% of change during the year
1	Anurag Ratan Kumar Shah	6,25,000	46.58%	0.00
2	Akshay Mahendra Parmar	3,12,500	23.29%	0.00
	<b>Total</b>	<b>9,37,500</b>	<b>69.86%</b>	

**Note 4**

**Reserve & Surplus**

Particulars	As on	As on
	March 31, 2023	March 31, 2022
<b>A) Securities Premium Reserve</b>		
At the beginning of the year	840.81	840.81
Addition during the year	495.24	-
Utilized during the year	-	-
Closing balance for the year	<b>1,336.05</b>	<b>840.81</b>
<b>B) Profit and Loss Account</b>		
At the beginning of the year	(323.68)	(371.53)
Profit for the year	133.69	47.78
Transferred during the year (Note 4.1)	(18.15)	0.07
Closing balance for the year	<b>(208.14)</b>	<b>(323.68)</b>
<b>Total</b>	<b>1,127.91</b>	<b>517.13</b>

**Note 4.1.** As per transition provision of AS-15 "Employee Benefits", the difference between transition liability is ₹18.15 Lakhs, adjusted against reserves and surplus.



*Om ar ma*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

**Note 5**

**Long-term borrowings**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>A) Secured</b>		
1) <b>Term Loan</b>		
From Bank		
SIDBI loan in Foreign Currency	-	11.00
SIDBI loan in Indian Rupee Loan I	4.77	11.91
	4.77	22.91
<b>B) Unsecured</b>		
i) Loans and Advances from Directors, Related Parties and Shareholders	1,105.28	1,107.35
	1,105.28	1,107.35
<b>Total</b>	<b>1,110.05</b>	<b>1,130.26</b>

**Terms, Conditions and Other Material Information in respect of Term Loans from SIDBI**  
31-03-2023

SR. NO.	PARTICULARS	SIDBI LOAN IN FOREIGN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY
1	Nature of Loan	Foreign Currency Term Loan	Mortgage
2	Date of Disbursal	27.07.2018- 1st Tranche amounting to ₹ 30 Lakhs; 30.08.2018- 2nd and balance tranche amounting to ₹ 30 Lakhs	10-12-2020
3	Loan Amount	INR 60 Lakhs (USD 87273)	21.43 Lakhs
4	Repayment Mode	EMI	EMI
5	Amount of each Instalment	US \$1819 for 47 months & 1 installment for US \$ 1780 in the last month	Principal payment of ₹ 0.60 Lakhs for first 35 months & ₹ 60 Lakhs for last month.
6	Total number of monthly instalments	48	36
7	Repayment Start Date	08-07-2019	10-12-2021
8	Rate of Interest	3.7883% P.A. (PLUS)	8.25%
9	Additional rate of interest (in case of default)	2%	2%
10	Security	Office premises- H - 13/14 Everest, 156 Tardeo Road, Mumbai 400034	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired /to be acquired under the project/scheme
11	Guarantee	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors
12	Current portion of outstanding amount classified as Current Liability	11.09	7.14
13	Non-Current portion of outstanding amount classified as Non-Current Liability	0	4.77
	<b>Amount outstanding as on 31-03-2023</b>	<b>11.09</b>	<b>11.91</b>

31-03-2022

SR. NO.	PARTICULARS	SIDBI LOAN IN FOREIGN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY
1	Nature of Loan	Foreign Currency Term Loan	Mortgage
2	Date of Disbursal	27.07.2018- 1st Tranche amounting to ₹ 30 Lakhs; 30.08.2018- 2nd and balance tranche amounting to ₹ 30 Lakhs	10-12-2020
3	Loan Amount	INR 60 Lakhs (USD 87273)	21.43 Lakhs
4	Repayment Mode	EMI	EMI
5	Amount of each Instalment	US \$1819 for 47 months & 1 installment for US \$ 1780 in the last month	Principal payment of ₹ 0.60 Lakhs for first 35 months & ₹ 60 Lakhs for last month.
6	Total number of monthly instalments	48	36
7	Repayment Start Date	08-07-2019	10-12-2021
8	Rate of Interest	3.7883% P.A. (PLUS)	8.25%
9	Additional rate of interest (in case of default)	2%	2%
10	Security	Office premises- H - 13/14 Everest, 156 Tardeo Road, Mumbai 400034	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired /to be acquired under the project/scheme
11	Guarantee	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors
12	Current portion of outstanding amount classified as Current Liability	16.55	7.14
13	Non-Current portion of outstanding amount classified as Non-Current Liability	11.00	11.91
	<b>Amount outstanding as on 31-03-2022</b>	<b>27.55</b>	<b>19.05</b>



*Dmama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

**Note 6**

**Short Term Borrowings**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>A) Loan Renewable on Demand - Secured</b>		
a) From Banks		
Bank Overdraft (Note 6.1)	79.48	-
Bank of Baroda	-	6.35
Dena Bank	79.48	6.35
<b>B) Current Maturity of Long term debts</b>	18.24	23.69
<b>Total</b>	<b>97.72</b>	<b>30.04</b>

Note 6.1. Bank Overdraft of ₹ 79,48,301 is secured against the Fixed Deposit owned by Director.

**Note 7**

**Trade Payables**

Particulars	As on March 31, 2023	As on March 31, 2022
Due to Micro and Small Enterprises	0.55	0.55
Other Payables ( Other than Micro and Small Enterprises)	2.50	3.77
<b>Total</b>	<b>3.05</b>	<b>4.32</b>

**7.1. Ageing Schedule**

Figures For the Current Reporting Period i.e. 31 March 2023

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	-	0.54	0.01	-	0.55
Others	2.24	0.21	0.03	0.02	2.50
Dispute dues-MSME	-	-	-	-	-
Dispute dues- Others	-	-	-	-	-
<b>Total</b>	<b>2.24</b>	<b>0.75</b>	<b>0.04</b>	<b>0.02</b>	<b>3.05</b>

Figures For Previous Reporting Period i.e. 31 March 2022

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	0.55	-	-	-	0.55
Others	3.04	0.03	0.70	-	3.77
Dispute dues-MSME	-	-	-	-	-
Dispute dues- Others	-	-	-	-	-
<b>Total</b>	<b>3.59</b>	<b>0.03</b>	<b>0.70</b>	<b>-</b>	<b>4.32</b>

**7.2. DETAILS OF DUES TO MICRO AND SMALL ENTERPRISES AS DEFINED UNDER THE MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006**

On the basis of confirmation obtained from suppliers who have registered themselves under the Micro Small Medium Enterprise Development Act, 2006 (MSMED Act, 2006) and based on the information available with the Company, the following are the details:

	As on March 31, 2023	As on March 31, 2022
a. The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year:		
- The principal amount remaining unpaid to any supplier at the end of accounting year included in trade payables	0.55	0.55
- Interest due on overdue	0.10	0.04
b. The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year	-	-
c. The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro, Small and Medium Enterprises Development Act, 2006.	-	-
d. The amount of interest accrued and remaining unpaid at the end of each accounting year	0.10	0.04
e. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of Micro, Small and Medium Enterprises Development Act, 2006.	-	-

**Note 8**

**Other current liabilities**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>Other Payables</b>		
a) Advance from customers	0.01	-
b) Statutory Liabilities	3.69	5.10
c) Expenses Payable	35.12	31.12
<b>Total</b>	<b>38.82</b>	<b>36.22</b>

**Note 9**

**Short Term Provisions**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>A) Provision for Employee benefits</b>		
a) Gratuity	18.56	-
<b>Total</b>	<b>18.56</b>	<b>-</b>



*am/am*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

Note 10

Property, plant and Equipment and Intangible Assets

(₹ in Lakhs)

Period ended 31st March, 2023

SR. NO.	PARTICULARS	GROSS BLOCK AT COST				DEPRECIATION				NET BLOCK	
		AS ON 31-03-2022	ADDITIO N	DEDUCTIO N	AS ON 31-03-2023	AS ON 01-04-2022	FOR THE YEAR	DEDUCTIO N	AS ON 31-03-2023	AS ON 31-03-2023	AS ON 31-03-2022
(i) 1	<u>Property, Plant and</u> Buildings	235.05	0.00	0.00	235.05	90.15	7.06	0.00	97.21	137.84	144.90
2	Furnitures & Fixtures	25.62	0.00	0.00	25.62	21.52	1.05	0.00	22.57	3.05	4.10
3	Electrical Equipment	0.36	0.00	0.00	0.36	0.34	0.00	0.00	0.34	0.02	0.02
4	Computer	7.56	0.06	0.00	7.62	7.18	0.01	0.00	7.19	0.43	0.38
5	Office Equipment	1.43	0.00	0.00	1.43	1.30	0.02	0.00	1.32	0.11	0.13
6	Vehicle	7.89	0.00	0.00	7.89	7.32	0.16	0.00	7.48	0.41	0.57
	<b>TOTAL (A)</b>	<b>277.91</b>	<b>0.06</b>	<b>0.00</b>	<b>277.97</b>	<b>127.81</b>	<b>8.30</b>	<b>0.00</b>	<b>136.11</b>	<b>141.86</b>	<b>150.10</b>
(ii)	<u>Intangible Assets</u>										
	Computer Software	6.26	0.00	0.00	6.26	5.95	0.00	0.00	5.95	0.31	0.31
	<b>TOTAL (B)</b>	<b>6.26</b>	<b>0.00</b>	<b>0.00</b>	<b>6.26</b>	<b>5.95</b>	<b>0.00</b>	<b>0.00</b>	<b>5.95</b>	<b>0.31</b>	<b>0.31</b>
	<b>TOTAL (A+B)(Current Year)</b>	<b>284.17</b>	<b>0.06</b>	<b>0.00</b>	<b>284.23</b>	<b>133.76</b>	<b>8.30</b>	<b>0.00</b>	<b>142.06</b>	<b>142.17</b>	<b>150.41</b>
	<b>(Previous Year)</b>	<b>284.17</b>	<b>0.00</b>	<b>0.00</b>	<b>284.17</b>	<b>124.46</b>	<b>9.30</b>	<b>0.00</b>	<b>133.76</b>	<b>150.41</b>	<b>159.71</b>

Period ended 31st, March 2022

SR. NO.	PARTICULARS	GROSS BLOCK AT COST				DEPRECIATION				NET BLOCK	
		AS ON 31.03.2021	ADDITIO N	DEDUCTIO N	AS ON 31.03.2022	AS ON 01.04.2021	FOR THE YEAR	DEDUCTIO N	AS ON 31.03.2022	AS ON 31.03.2022	AS ON 31.03.2021
(i) 1	<u>Property, Plant and</u> Buildings	235.05	0.00	0.00	235.05	82.73	7.42	0.00	90.15	144.90	152.32
2	Furnitures & Fixtures	25.62	0.00	0.00	25.62	20.08	1.44	0.00	21.52	4.10	5.54
3	Electrical Equipment	0.36	0.00	0.00	0.36	0.34	0.00	0.00	0.34	0.02	0.02
4	Computer	7.56	0.00	0.00	7.56	7.18	0.00	0.00	7.18	0.38	0.38
5	Office Equipment	1.43	0.00	0.00	1.43	1.26	0.04	0.00	1.30	0.13	0.17
6	Vehicle	7.89	0.00	0.00	7.89	7.10	0.22	0.00	7.32	0.57	0.79
	<b>TOTAL (A)</b>	<b>277.91</b>	<b>0.00</b>	<b>0.00</b>	<b>277.91</b>	<b>118.69</b>	<b>9.12</b>	<b>0.00</b>	<b>127.81</b>	<b>150.10</b>	<b>159.22</b>
(ii)	<u>Intangible Assets</u>										
	Computer Software	6.26	0.00	0.00	6.26	5.77	0.18	0.00	5.95	0.31	0.49
	<b>TOTAL (B)</b>	<b>6.26</b>	<b>0.00</b>	<b>0.00</b>	<b>6.26</b>	<b>5.77</b>	<b>0.18</b>	<b>0.00</b>	<b>5.95</b>	<b>0.31</b>	<b>0.49</b>
	<b>TOTAL (A+B)(Current year)</b>	<b>284.17</b>	<b>0.00</b>	<b>0.00</b>	<b>284.17</b>	<b>124.46</b>	<b>9.30</b>	<b>0.00</b>	<b>133.76</b>	<b>150.41</b>	<b>159.71</b>
	<b>(Previous Year)</b>	<b>284.17</b>	<b>0.00</b>	<b>0.00</b>	<b>284.17</b>	<b>113.91</b>	<b>10.55</b>	<b>0.00</b>	<b>124.46</b>	<b>159.71</b>	<b>170.25</b>



*Omama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

Note 11 (₹ in Lakhs)

Particulars	As on	As on
	March 31, 2023	March 31, 2022
<b>(b) Non-current investments</b>		
<b>A) Trade Investments</b>		
a) <u>Investment in Equity Instruments</u>		
i) <u>of Subsidiaries</u>		
Aryvarta FZE ( RAKEZ, UAE) (100%)	8.85	8.85
Unihealth Pharmaceuticals Pvt Ltd (100%)	19.25	-
Biohealth Ltd. ( Tanzania) (99.01%)	51.51	51.51
Unihealth Tanzania Ltd. (Tanzania) (80%)	23.23	23.23
ii) <u>of Joint Ventures</u>		
UMC Global Health Ltd. (Nigeria) (50%)	10.25	10.25
Victoria Hospital Ltd. (Uganda) (50%)	460.39	460.39
iii) <u>of Associates</u>		
Unihealth Uganda Limited (Uganda) (45%)	60.39	60.39
<b>B) Others</b>		
a) <u>Investments in Shares</u>		
Rajkot Bank	-	0.01
	<b>633.87</b>	<b>614.62</b>
Aggregate amount of Unquoted Investments	633.87	614.62
Aggregate amount of other Investments	-	0.01
<b>Total</b>	<b>633.87</b>	<b>614.62</b>

Note 12

Particulars	As on	(Charge) / Credit in	As on
	March 31, 2023	Statement of profit and loss	March 31, 2022
Deferred Tax Asset/ (Liability)	-	-	-
Accrued Expense allowed on payment basis	0.10	0.10	-
Brought forward losses	22.58	22.58	-
Depreciation difference	(0.36)	(0.36)	-
<b>Deferred Tax Assets/ (Liabilities) (Net)</b>	<b>22.32</b>	<b>22.32</b>	<b>-</b>

Note 13

Particulars	As on	As on
	March 31, 2023	March 31, 2022
<b>(d) Long term loans and advances</b>		
<u>Unsecured, Considered Good</u>		
Loans and Advances to Related Parties	1,484.61	688.11
<b>Total</b>	<b>1,484.61</b>	<b>688.11</b>

Note 14

Particulars	As on	As on
	March 31, 2023	March 31, 2022
<b>(e) Other non-current assets</b>		
Security Deposits	2.00	1.93
Others	89.15	62.92
<b>Total</b>	<b>91.15</b>	<b>64.85</b>



**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

**Note 15**  
**(c) Trade receivables**

Particulars	As on	As on
	March 31, 2023	March 31, 2022
Secured, Considered Good	-	-
Unsecured, Considered Good	62.44	209.84
Doubtful	-	-
<b>Total</b>	<b>62.44</b>	<b>209.84</b>

**15.1. Ageing Schedule**

**Figures For the Current Reporting Period i.e. 31 March 2023**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Good	42.53	0.76	-	-	19.15	62.44
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Good	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
<b>Total</b>	<b>42.53</b>	<b>0.76</b>	<b>-</b>	<b>-</b>	<b>19.15</b>	<b>62.44</b>

**Figures For the Previous Reporting Period i.e. 31 March 2022**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Good	119.41	-	-	-	90.43	209.84
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Good	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
<b>Total</b>	<b>119.41</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>90.43</b>	<b>209.84</b>

**Note 16**

**(d) Cash and cash equivalents**

Particulars	As on	As on
	March 31, 2023	March 31, 2022
A) Cash in Hand	0.05	0.01
B) Bank Balances	3.60	5.04
C) Other Bank Balance(Fixed Deposit)	-	9.88
<b>Total</b>	<b>3.65</b>	<b>14.92</b>

**Note 17**

**(e) Short-term loans and advances**

Particulars	As on	As on
	March 31, 2023	March 31, 2022
<b>Unsecured, Considered Good</b>		
A) Loans and advances to Employees	28.46	27.46
B) Prepaid Expenses	0.21	0.13
C) Others	6.00	7.05
<b>Total</b>	<b>34.67</b>	<b>34.64</b>

**Note 18**

**Others Current Assets**

Particulars	As on	As on
	March 31, 2023	March 31, 2022
A) Balance with government Authorities	60.18	69.77
B) Others		
a) <u>Unsecured Considered Good</u> Receivable from Debtors	-	5.00
<b>Total</b>	<b>60.18</b>	<b>74.77</b>



*Amama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

(₹ in Lakhs)

**Note 19**

**Revenue from Operations**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>Sale of Services</b>		
Export of consultancy Services	120.82	109.85
Consultancy Services -In Country	71.67	51.63
<b>Total</b>	<b>192.49</b>	<b>161.48</b>

**Note 20**

**Other Income**

Particulars	As on March 31, 2023	As on March 31, 2022
a) <b>Interest Income</b>		
Interest on loan	98.19	69.48
interest on FDR's	0.36	0.48
b) <b>Other Non-Operating Income</b>		
Exchange Gain on Transactions	76.54	21.58
Rent receipts	3.50	2.94
Others	0.03	-
<b>Total</b>	<b>178.62</b>	<b>94.48</b>

**Note 21**

**Employee benefit expenses**

Particulars	As on March 31, 2023	As on March 31, 2022
Salaries and Wages	50.91	42.99
Gratuity	0.41	-
Contribution to Provident and other funds	1.04	1.06
Staff Welfare	0.16	0.08
<b>Total</b>	<b>52.52</b>	<b>44.13</b>

**Note 22**

**Finance cost**

Particulars	As on March 31, 2023	As on March 31, 2022
<b>Interest Expense</b>		
Interest on Overdraft Facility	1.37	-
Interest on Bank Term Loan	2.43	3.17
Interest on Other Loans	111.61	115.58
<b>Total</b>	<b>115.41</b>	<b>118.75</b>



*@mama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

(₹ in Lakhs)

**Note 23**

**Other expenses**

Particulars	As on March 31, 2023	As on March 31, 2022
Auditor's Remuneration	5.60	2.90
Bank Charges	2.33	0.70
Coneyance and Travelling expense	6.54	2.85
Hotel Boarding/Lodging Expenses	2.04	-
Insurance	0.16	0.06
Legal and Professional Fees	4.28	8.51
Medical Treatment	5.11	-
Miscellaneous Expenses	7.44	5.71
Rates and Taxes	21.49	0.02
Rent	5.32	6.02
Software Maintenance Charges	4.47	4.25
Sundry Balances Written off	18.73	4.98
<b>Total</b>	<b>83.51</b>	<b>36.00</b>

**Payment to Auditors (exluding taxes)**

Particulars	As on March 31, 2023	As on March 31, 2022
Statutory Audit	3.25	1.55
Other services	2.35	1.35
<b>Total</b>	<b>5.60</b>	<b>2.90</b>

**Note 24**

**Earnings per equity share**

Particulars	As on March 31, 2023	As on March 31, 2022
Profit for the year (A)	133.69	47.78
Weighted number of equity shares outstanding (B)(in numbers)	13,42,136	13,41,875
Face Value per Equity Shares in ₹	10.00	10.00
Basic EPS (in ₹)	9.96	3.56
Diluted EPS (in ₹)	9.96	3.56





**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March,**

**Note-25**

**Related Party Transactions**

**A) Names of related parties and nature of relationship**

**i) Key Managerial Personnel(KMP)**

<u>Name of Person</u>	<u>Relation</u>
Akshay Mahendra Parmar	Managing Director
Anurag Ratankumar Shah	Director
Parag Rajnikant Shah	Whole Time Director & Chief Financial Officer

**ii) Entities under common control**

Aarzeal Technologies Private Limited  
Aryavarta Trading Private Limited  
Unity Forgings Private Limited  
Unihealth Foundation

**iii) Subsidiary Companies**

Aryavarta FZE  
Biohealth Limited  
Unihealth Pharmaceuticals Private Limited  
Unihealth Tanzania Limited

**iv) Joint Ventures**

Victoria Hospital Limited  
UMC Global Health Limited

**v) Associate Companies**

Unihealth Uganda Limited

**vi) Relatives of KMP**

Mayuri Akshay Parmar  
Mahendra H Parmar  
Prafulla Mahendra Parmar  
Aryan Akshay Parmar  
Dhruv Akshay Parmar  
Ratan Kumar Shah  
Sangeeta Shah  
Parag Ratankumar Shah  
Shital Parag Shah  
Rajnikant Damodardas Shah  
Gitaben Rajnikant Shah  
Jainil Parag Shah  
Dipansh Rajnikant Shah  
Ketan Rajnikant Shah  
Neha Jaimin Shah



*Dmama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
**Notes To Standalone Financial Statements for the period ended 31st March, 2023**

**B) Transactions with related parties**

(₹ in Lakhs)

Details of the Related Parties	Transactions		Balances	
	March 31,2023	March 31,2022	March 31,2023	March 31,2022
<b>a) Victoria Hospital Limited</b>				
Export of Goods/Services	120.82	106.13		
Loan given	656.44	13.34	1,477.40	809.51
Interest receivable	81.44	65.50		
<b>b) Aarzeal Technologies Private Limited</b>				
Rental Service (Including Taxes)	1.42	1.42	-	0.24
<b>c) Unihealth Pharmaceuticals Private Limited</b>				
Rental Service (Including Taxes)	2.05	2.05	-	0.17
Others	0.02	0.03		
<b>d) Biohealth Limited</b>				
Management Consultancy Services	-	-		
Loan Given	36.02	1.00	99.79	54.70
Interest receivable	7.58	3.97		
<b>e) Unihealth Tanzania Limited</b>				
Loan Given	41.11	-	41.23	-
Interest receivable	0.12	-		
<b>f) Akshay M. Parmar</b>				
Director Remuneration	4.50	-		
Interest on Unsecured loan	-	-	52.25	17.95
Loan taken during the year	87.76	30.25		
Loan repaid during the year	53.46	34.70		
<b>g) Anurag R Shah</b>				
Director Remuneration	-	-		
Interest on Unsecured loan	-	-	98.64	67.65
Loan taken during the year	36.65	81.90		
Loan repaid during the year	5.66	64.31		
<b>h) Parag R Shah</b>				
Director Remuneration	6.60	6.60	-	-
<b>i) Mayuri A Parmar</b>				
Interest on Unsecured loan	-	-		
Loan taken during the year	125.65	19.50	117.25	0.50
Loan repaid during the year	8.90	19.00		
<b>j) Prafulla M Parmar</b>				
Interest on Unsecured loan	-	-		
Loan taken during the year	145.00	4.75	149.75	4.75
Loan repaid during the year	-	207.35		
<b>k) Mahendra H Parmar</b>				
Interest on Unsecured loan	-	-		
Loan taken during the year	225.40	61.00	250.40	25.00
Loan repaid during the year	-	153.45		



*Amama*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

**26 Contingent liabilities and Commitments**

(₹ in Lakhs)

Particulars	31st March, 2023	31st March, 2022
(i) Contingent Liabilities		
Details of Claims against the Company not acknowledged as Debt include:		
respect of:		
FY 2012-13	0.22	0.12
FY 2015-16	0.09	0.09
FY 2016-17	454.35	434.28
FY 2017-18	394.41	326.16
(ii) Commitments	-	-
<b>Total</b>	<b>849.07</b>	<b>760.44</b>

**27 Details of Gratuity Plan is as follows:**

Assumptions (Closing Period)		
Particulars	As at 31/03/23	As at 31/03/22
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	7.52%	7.23%
Rate of Salary Increase	5.00%	5.00%
Rate of Employee Turnover	5.00%	-
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)

Table Showing Change in the Present Value of Defined Benefit Obligation		
Particulars	As at 31/03/23	As at 31/03/22
Present Value of Benefit Obligation at the Beginning of the Period	18.15	-
Interest Cost	-	-
Current Service Cost	1.69	-
Past Service Cost - Non-Vested Benefit Incurred During the Period	-	-
Past Service Cost - Vested Benefit Incurred During the Period	-	-
Liability Transferred In/ Acquisitions	-	-
(Liability Transferred Out/ Divestments)	-	-
(Gains)/ Losses on Curtailment	-	-
(Liabilities Extinguished on Settlement)	-	-
(Benefit Paid Directly by the Employer)	-	-
(Benefit Paid From the Fund)	-	-
The Effect Of Changes in Foreign Exchange Rates	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	(0.45)	-
Actuarial (Gains)/Losses on Obligations - Due to Experience	(0.84)	-
Present Value of Benefit Obligation at the End of the Period	18.56	-

Actuarial (Gains)/ losses recognized in the Statement of Profit or Loss for Current Period		
Particulars	As at 31/03/23	As at 31/03/22
Actuarial (Gains)/Losses on Obligation For the Period	(1.29)	-
Actuarial (Gains)/Losses on Plan Asset For the Period	-	-
Subtotal	(1.29)	-
Actuarial (Gains)/Losses Recognized in the Statement of Profit or loss	(1.29)	-

Amount Recognized in the Balance Sheet		
Particulars	As at 31/03/23	As at 31/03/22
(Present Value of Benefit Obligation at the end of the Period)	(18.56)	-
Fair Value of Plan Assets at the end of the Period	-	-
Funded Status (Surplus/ (Deficit))	(18.56)	-
Unrecognized Past Service Cost at the end of the Period	-	-
Net (Liability)/Asset Recognized in the Balance Sheet	(18.56)	-



*Amal*

**UNIHEALTH CONSULTANCY PRIVATE LIMITED**  
Notes To Standalone Financial Statements for the period ended 31st March, 2023

Expense Recognized in the Statement of Profit or Loss		
Particulars	As at 31/03/23	As at 31/03/22
Current Service Cost	1.69	-
Net Interest Cost	-	-
Actuarial (Gains)/Losses	(1.29)	-
Past Service Cost - Non-Vested Benefit Recognized During the Period	-	-
Past Service Cost - Vested Benefit Recognized During the Period	-	-
(Expected Contributions by the Employees)	-	-
(Gains)/Losses on Curtailments And Settlements	-	-
Net Effect of Changes in Foreign Exchange Rates	-	-
Change in Asset Ceiling	-	-
Expenses Recognized in the Statement of Profit or Loss	0.41	-

28 Earnings per share calculated and shown in profit and loss account in note 24 are calculated as per Accounting standard 20 issued by the Institute of Chartered Accountant of India.

**29 Earning in foreign currency**

Description	Year ended March 31, 2023	Year ended March 31, 2022
Export Services	120.82	109.85
Interest income	98.19	69.47
<b>Total</b>	<b>219.01</b>	<b>179.32</b>

**30 Expenditure in foreign currency**

Description	Year ended March 31, 2023	Year ended March 31, 2022
Foreign Travelling Expense	4.03	2.85
<b>Total</b>	<b>4.03</b>	<b>2.85</b>

**31 Material events occurring after the date of Standalone Financial Statements.**

In line with Accounting Standard 4, following non adjusted material events occurred after the period of restated consolidated Financial Information:

- 1 Pursuant to a resolution passed by Board of Directors of the company on January 4, 2023, the Company has approved to become first subscriber to Memorandum of Association of UHS Oncology Private Limited by subscribing to its Memorandum of Association (MOA) for 3,333 no. of equity shares in the incorporation on 16th January, 2023, amounting to ₹ 33,333. Payment for the said subscription was effected on May 18, 2023.
- 2 Pursuant to a resolution passed by Board of Directors of the company on 27th April, 2023 and a resolution passed by the Shareholders in the EGM held on 29th April, 2023 the company has approved issuance of 97,26,458 no. of Equity Shares of Rs. 10 each as Bonus Shares in the ratio of 7:1 out of Security Premium Reserve Account.
- 3 Name of the Company was changed from Unihealth Consultancy Private Limited (CIN U85100MH2010PTC200491) to Unihealth Consultancy Limited (CIN U85100MH2010PLC200491) w.e.f. 26th April, 2023 vide Certificate of Incorporation Consequent upon conversion to public company issued by ROC Mumbai. The Company is in process of getting listed on Small and Medium Enterprise ("SME") platform of National Stock Exchange (NSE).
- 32 There are no transactions which were not recorded in books of accounts and have been surrendered or disclosed as income during the year in the tax assessments under Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- 33 The company has not revalued Property, Plant and Equipment.
- 34 Loans or Advances in the nature of loans are granted to Related Parties (Subsidiaries- Biohealth limited & Unihealth Tanzania Limited, Joint Venture- Victoria Hospital Limited) which are repayable in a single or in multiple tranches/ installments at any mutually agreed time within the tenure of the Loan as per the agreement entered with the Parties.
- 35 No proceedings have been initiated or pending against Company for holding any Benami Property under Prohibitions of Benami Transactions Act, 1988 (Earlier titled as Benami Transactions (Prohibitions) Act, 1988.
- 36 The Company has borrowings from Banks or Financial Institutions on the security of Fixed Deposits in India, however, no quarterly return or statement is required to be filed with the bank or Financial Institution.
- 37 The Company has not been declared as willful defaulter.
- 38 During the year, the Company has not executed any transaction with Companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956.
- 39 No charges are pending for registration or satisfaction with the Registrar of Companies (ROC).
- 40 The Company is in compliance with the no. of layers as prescribed under clause (87) of section 2 of The Companies Act, 2013 read with the Companies (Restriction on Number of Layers) Rules, 2017.
- 41 (A) The Company has not advanced or loaned or invested funds, with any understanding, to any other person(s) or entity(ies), including foreign entities (Intermediaries) that the Intermediary shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
 (B) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding
  - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries)
  - (b) Provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- 42 Corporate Social Responsibility -Section 135 of the Companies Act is not applicable to the Company.
- 43 Previous year's figures have been regrouped, rearranged or recasted to make them comparable wherever necessary.



*Emam*